新天药业(002873) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥156,411,465.16, representing a 6.41% increase compared to ¥146,986,626.23 in the same period last year[8] - Net profit attributable to shareholders was ¥17,125,823.30, up 11.25% from ¥15,393,861.17 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥16,890,823.30, reflecting a 17.73% increase from ¥14,346,626.73 in the previous year[8] - The estimated net profit for the first half of 2018 is projected to be between 32.60 million yuan and 37.05 million yuan, representing a growth of 10% to 25% compared to 29.64 million yuan in the same period of 2017[19] - The increase in net profit is primarily attributed to business growth[19] Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 94.68%, amounting to ¥1,341,814.45 compared to ¥25,232,573.52 in the same period last year[8] - Total assets at the end of the reporting period were ¥914,718,605.96, a 6.81% increase from ¥856,403,946.15 at the end of the previous year[8] - Prepayments increased by 98.81% to ¥14,371,785.13, primarily due to increased payments for project research and equipment[15] - Other receivables surged by 202.73% to ¥18,674,742.50, mainly due to an increase in market reserve funds[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,972[10] - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., held 43.94% of the shares, totaling 30,265,766 shares[11] Corporate Governance - The company reported no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[18] - There were no violations regarding external guarantees during the reporting period[22] - The company did not experience any non-operating fund occupation by controlling shareholders or related parties during the reporting period[23] - No research, communication, or interview activities were conducted during the reporting period[24] Profit Distribution - The company proposed a profit distribution plan for 2017, distributing a cash dividend of 2 yuan per 10 shares and a capital reserve increase of 10 shares for every 10 shares held[16] Financial Assets - The fair value of financial assets includes an initial investment of 1,255,000 yuan, with a current fair value change of 429,250 yuan, leading to a total amount of 7,185,000 yuan[21] Return on Equity - The company's weighted average return on equity decreased to 2.72% from 5.08% year-on-year, a decline of 2.36%[8]